^
Association details:
| Biomarker: | MET elevation |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase II and Biomarker Study of Cabozantinib in Patients with Advanced Cholangiocarcinoma
Excerpt:
Previously treated patients with unresectable or metastatic cholangiocarcinoma received cabozantinib...Of the baseline biomarkers, low plasma TIMP-1 was associated with longer PFS (p=0.029), and low IL-6 (p=0.021) and high sMET (p=0.0027) were correlated with longer OS.
DOI:
https://dx.doi.org/10.1002%2Fcncr.30571
Trial ID:
